#United States #Cranford #EVERSANA #LYMPHIR #Citius Oncology

Citius Oncology and EVERSANA: A Strategic Alliance for LYMPHIR™ Launch

Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, has taken a significant step forward in expanding its commercial reach. On October 16, 2025, the company announced the signing of an exclusive commercialization agreement with EVERSANA, a leading provider of global commercialization services. This partnership aims to facilitate the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl), a targeted therapy approved by the FDA for relapsed or refractory cutaneous T-cell lymphoma (CTCL).

The Role of EVERSANA

Under the terms of the Master Service Agreement, EVERSANA will play a vital role in ensuring a successful launch of LYMPHIR, scheduled for the fourth quarter of 2025. The agreement covers a wide range of services, including ongoing medical information, pharmacovigilance, and revenue cycle management, which are critical for both pre- and post-launch operations.

Leonard Mazur, Chairman and CEO of Citius Oncology, emphasized that this collaboration is pivotal as it leverages EVERSANA's infrastructure and expertise in oncology commercialization. He noted, “Finalizing our exclusive agreement with EVERSANA is a transformative milestone as we prepare to bring LYMPHIR to market.” This sentiment reflects Citius Oncology’s strategic focus on efficiently scaling its commercial capabilities and ensuring timely access for patients in need of this innovative treatment.

What is LYMPHIR™?

LYMPHIR™ is a recombinant fusion protein that selectively targets malignant T-cells in patients with CTCL, where traditional treatments may fall short. Approved by the FDA in August 2024, it aims to alleviate the symptoms caused by this challenging cancer type, which does not have many effective treatment options available.

CTCL impacts the skin with lesions caused by cancerous T-cells, significantly diminishing the quality of life due to complications such as severe pain and itchiness. The most common subtypes, Mycosis Fungoides and Sézary Syndrome, require innovative therapeutic approaches to manage their progression effectively.

Looking Ahead

With clinical data supporting LYMPHIR's efficacy and safety for use after at least one prior systemic therapy, Citius Oncology is optimistic about addressing an unmet medical need in the oncology space. The estimated market for CTCL treatments is currently expanding, with Citius's leadership highlighting their commitment to providing valuable therapeutic options for patients.

Greg Skalicky, President of EVERSANA, shared his enthusiasm for the partnership saying, “This agreement reflects our shared mission to deliver innovative cancer treatments to patients who need them.”

In summary, the partnership between Citius Oncology and EVERSANA represents a crucial collaboration aimed at improving the patient experience within oncology. As they approach the late 2025 launch, both companies are dedicated to ensuring that LYMPHIR™ reaches the patients who need it, potentially transforming the landscape of CTCL treatment.

Safety Information

As with any therapeutic product, LYMPHIR comes with potential risks, including the serious capillary leak syndrome that may affect patients during treatment. The clinical trials reported a significant occurrence of infusion-related reactions, highlighting the importance of close monitoring and patient assessment during therapy. The comprehensive safety data reflects Citius’s commitment to patient care, reminding healthcare providers to stay vigilant during the administration of LYMPHIR.

For comprehensive details about LYMPHIR, including potential side effects and contraindications, it’s advisable for patients and healthcare providers to consult the prescribing information or discuss it with a qualified medical professional.

By collaborating with EVERSANA, Citius Oncology aims not only to launch a product but to make a meaningful difference in the lives of those affected by CTCL. As the healthcare landscape continues to evolve, partnerships like this signify a forward-thinking approach to treating complex diseases with innovative therapies.